MALDI mass spectrometry
BioMérieux Gets FDA 510(k) Clearance for MALDI-TOF Bacterial ID System
The next-generation system, which received CE marking last year, identifies bacteria more rapidly and is now commercially available in the US.
Agilent Q3 Revenues Up 6 Percent
The firm's diagnostics and genomics group saw an 11 percent year-over-year revenue increase in the third quarter.
The company aims to launch a CE-IVD-marked MALDI system in 2021 that will identify bacteria in urinary tract infections without requiring sample culturing.
Biodesix, MRM Proteomics Partner on Lung Cancer Assays
Under the agreement, MRM Proteomics has granted Biodesix rights to use its iMALDI mass spectrometry technologies to develop blood-based tests for lung cancer.
MRM Proteomics Collaborating With Exactis to Develop MALDI Assays for Guiding Cancer Treatment
Premium
MRM will develop immuno-MALDI mass spec assays to key cancer signaling proteins and test them in 100 breast and colorectal cancer samples provided by Exactis.